High Point Advisor Group LLC Nektar Therapeutics Transaction History

High Point Advisor Group LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 13, 2020	SELL	$15.87 - $23.12 $144,067 - $209,883	-9,078 Closed	0 $0
Q3 2019 Nov 12, 2019	SELL	$16.91 - $36.27 $84,803 - $181,894	-5,015 Reduced 35.59%	9,078 $181,000
Q2 2019 Aug 15, 2019	BUY	$31.0 - $36.3 $12,214 - $14,302	394 Added 2.88%	14,093 $455,000
Q1 2019 May 08, 2019	BUY	$31.58 - $46.35 $3,600 - $5,283	114 Added 0.84%	13,699 $439,000
Q4 2018 Feb 20, 2019	BUY	$30.43 - $56.65 $81,856 - $152,388	2,690 Added 24.69%	13,585 $581,000

Q3 2018 Oct 24, 2018	SELL	$46.46 - $68.49 $20,442 - $30,135	-440 Reduced 3.88%	10,895 $435,000
Q2 2018 Aug 20, 2018	BUY	$46.25 - $104.45 $209,142 - $472,322	4,522 Added 66.37%	11,335 $680,000
Q1 2018 Jun 11, 2018	BUY	$57.4 - $108.44 $391,066 - $738,801	6,813 New	6,813 $369,000
Q4 2017 Feb 15, 2018	SELL	$23.02 - $60.5 $421,266 - $1.11 Million	-18,300 Closed	0 $0
Q3 2017 Nov 06, 2017	BUY	$17.79 - $24.0 $325,557 - $439,200	18,300	18,300 $431,000

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $219M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of High Point Advisor Group LLC, based on Form 13F filings with the SEC.

Stay updated on High Point Advisor Group LLC with notifications on news.